In 2010, the Pre-exposure Prophylaxis Initiative (iPrEx) trial of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection used a combination of daily oral tenofovir disoproxil fumarate and emtricitabine to demonstrate an overall 44% reduction in HIV acquisition among men who have sex with men (MSM) and transgender women receiving PrEP and greater than 90% efficacy among those with detectable drug levels in blood samples.
1 After 2 additional randomized clinical trials demonstrated safety and efficacy,
2,3 this PrEP formulation was approved in the United States for the prevention of sexually acquired HIV infection in 2012.
4 Two recent studies of daily or intermittent PrEP among MSM
5,6 confirmed high PrEP efficacy.